MTOR and ovarian cancer: Indeed, a recent study in ovarian cancer suggested that a combination of the FGFR inhibitor infigratinib and the mTOR inhibitor rapamycin induced remarkable cell cycle arrest and apoptosis in ovarian cancer cells, and reduced tumor size in the xenograft animals after the treatment.